Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-22
Based on 499 first isolates · MED-A · Cystitis (lower UTI) · 2025-03-23 → 2026-03-22
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 81 % (78 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
75 %
n = 32
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
81 %
84 %
n = 32
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
69 %
n = 32
ciprofloxacin CIP
trend · Escherichia coli
78 %
72 %
n = 32
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
75 %
n = 32
ceftriaxone CRO
trend · Escherichia coli
77 %
75 %
n = 32
71 %
66 %
n = 32
trimethoprim TMP
trend · Escherichia coli lower UTI only
66 %
63 %
n = 32
47 %
53 %
n = 32
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
19 %
n = 32
5 %
0 %
n = 32
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
6 %
n = 32

Most likely organisms for this profile

Escherichia coli
54 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.